gemcitabine + toceranib

Gemcitabine + toceranib is an investigational **combination regimen** pairing gemcitabine, a nucleoside analog antimetabolite chemotherapeutic, with toceranib phosphate, a small‑molecule multi–receptor tyrosine kinase inhibitor approved in veterinary oncology (Palladia) for canine mast cell tumors. Gemcitabine is intracellularly phosphorylated and incorporated into DNA, inhibiting DNA synthesis and inducing apoptosis in rapidly dividing tumor cells, while also inhibiting ribonucleotide reductase. Toceranib competitively inhibits the ATP‑binding sites of several receptor tyrosine kinases, including KIT, vascular endothelial growth factor receptors (VEGFRs), and platelet‑derived growth factor receptors (PDGFRs), thereby blocking signaling pathways involved in tumor proliferation, angiogenesis, and metastasis in dogs.[1][4] The rationale for combining these agents is to achieve complementary antineoplastic effects—direct cytotoxic DNA damage from gemcitabine plus targeted disruption of growth and angiogenic signaling from toceranib—although this specific doublet remains exploratory and is not an established standard regimen.